<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435081</url>
  </required_header>
  <id_info>
    <org_study_id>17049</org_study_id>
    <secondary_id>I4V-MC-JAIW</secondary_id>
    <nct_id>NCT03435081</nct_id>
  </id_info>
  <brief_title>A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis</brief_title>
  <acronym>BREEZE-AD5</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult
      participants with moderate to severe atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">August 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 with a ≥ 2 Point Improvement</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving IGA of 0 or 1 with a ≥ 2 point improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Eczema Area and Severity Index 75 (EASI75)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving EASI75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving EASI90</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving EASI90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline on EASI Score</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Percent change from baseline on EASI Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving SCORAD75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving a 4-Point Improvement on the Itch Numeric Rating Scale (NRS)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving a 4-Point improvement on the Itch NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the score of item #2 of the ADSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Skin Pain NRS</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in skin pain NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving EASI50</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving EASI50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving IGA of 0</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving IGA of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SCORAD</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in SCORAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving SCORAD90</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants achieving SCORAD90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Surface Area (BSA) Affected</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in BSA affected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Developing Skin Infections Requiring Antibiotic Treatment</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Proportion of participants developing skin infections requiring antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Itch NRS</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Percent change from baseline in Itch NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Total Score of the Patient Oriented Eczema Measure (POEM)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the total score of the POEM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Patient Global Impression of Severity—Atopic Dermatitis (PGI-S-AD) Score</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the PGI-S-AD score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Hospital Anxiety Depression Scale (HADS)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the HADS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the DLQI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Work Productivity and Activity Impairment - Atopic Dermatitis (WPAI-AD) Questionnaire</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the WPAI-AD questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the EQ-5D-5L</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally. Placebo administered orally to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally. Placebo administered orally to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of atopic dermatitis (AD) at least 12 months before screening.

          -  Have moderate to severe AD, including all of the following:

               -  EASI score ≥16

               -  IGA score of ≥3

               -  ≥10% of BSA involvement

          -  Have had inadequate response or intolerance to existing topical (applied to the skin)
             medications within 6 months preceding screening.

          -  Are willing to discontinue certain treatments for eczema (such as systemic and topical
             treatments during a washout period).

          -  Agree to use emollients daily.

        Exclusion Criteria:

          -  Are currently experiencing or have a history of other concomitant skin conditions
             (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory,
             or unstable skin disease that requires frequent hospitalizations and/or intravenous
             treatment for skin infections.

          -  A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode
             of eczema herpeticum in the past.

          -  Participants who are currently experiencing a skin infection that requires treatment,
             or is currently being treated, with topical or systemic antibiotics.

          -  Have any serious illness that is anticipated to require the use of systemic
             corticosteroids or otherwise interfere with study participation or require active
             frequent monitoring (e.g., unstable chronic asthma).

          -  Have been treated with the following therapies:

               -  monoclonal antibody for less than 5 half-lives before randomization

               -  received prior treatment with any oral Janus kinase (JAK) inhibitor less than 4
                  weeks before randomization

               -  received any parenteral corticosteroid administered by intramuscular or
                  intravenous injection within 6 weeks of planned randomization or are anticipated
                  to require parenteral injection of corticosteroids during the study

               -  have had an intra-articular corticosteroid injection within 6 weeks of planned
                  randomization

               -  probenecid at the time of randomization that cannot be discontinued for the
                  duration of the study

          -  Have high blood pressure characterized by a repeated systolic blood pressure &gt;160
             millimeters of mercury (mm Hg) or diastolic blood pressure &gt;100 mm Hg.

          -  Have had major surgery within the past eight weeks or are planning major surgery
             during the study.

          -  Have experienced any of the following within 12 weeks of screening: myocardial
             infarction (MI), unstable ischemic heart disease, stroke, or New York Heart
             Association Stage III/IV heart failure.

          -  Have a history of venous thromboembolic event (VTE), or are considered at high risk
             for VTE.

          -  Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver
             disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative
             disease or neuropsychiatric disorders or any other serious and/or unstable illness.

          -  Have a current or recent clinically serious viral, bacterial, fungal, or parasitic
             infection including herpes zoster, tuberculosis.

          -  Have specific laboratory abnormalities.

          -  Have received certain treatments that are contraindicated.

          -  Pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johnson Dermatology</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>479-649-3376</phone>
    </contact>
    <investigator>
      <last_name>Sandra Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Dermatology and Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>760-203-3839</phone>
    </contact>
    <investigator>
      <last_name>Stacy Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tien Q. Nguyen, MD inc. DBA First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-531-2966</phone>
    </contact>
    <investigator>
      <last_name>Tien Nguyen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>510-797-4111</phone>
    </contact>
    <investigator>
      <last_name>Sunil Dhawan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keck School of Medicine University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>323-865-3641</phone>
    </contact>
    <investigator>
      <last_name>April Armstrong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis-Dermatology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emanual Maverakis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>619-521-2830</phone>
    </contact>
    <investigator>
      <last_name>Daniel Marnell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-547-5151</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Soung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-828-8887</phone>
    </contact>
    <investigator>
      <last_name>Paul Yamauchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of CT/NY</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-616-2710</phone>
    </contact>
    <investigator>
      <last_name>Alice Gottlieb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Connecticut</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>860-679-4600</phone>
    </contact>
    <investigator>
      <last_name>Bruce Strober</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GWU/Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>202-741-2437</phone>
    </contact>
    <investigator>
      <last_name>Maria Sotomayor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Solutions Through Advanced Research, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>904-619-8157</phone>
    </contact>
    <investigator>
      <last_name>Pearl Kwong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riverchase Dermatology and Cosmetic Surgery</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-435-5100</phone>
    </contact>
    <investigator>
      <last_name>Robert Snyder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-974-4270</phone>
    </contact>
    <investigator>
      <last_name>Nishit Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Forward Clinical Trials, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-264-2155</phone>
    </contact>
    <investigator>
      <last_name>Seth Forman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatologic Surgery Specialists, PC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>478-742-2180</phone>
    </contact>
    <investigator>
      <last_name>David Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-939-9220</phone>
    </contact>
    <investigator>
      <last_name>Jamie Weisman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>912-443-4253</phone>
    </contact>
    <investigator>
      <last_name>Corinne Howington</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Treasure Valley Dermatology</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>208-467-3006</phone>
    </contact>
    <investigator>
      <last_name>Ryan Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-695-8106</phone>
    </contact>
    <investigator>
      <last_name>Jonathan Silverberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Dermatology</name>
      <address>
        <city>Darien</city>
        <state>Illinois</state>
        <zip>60561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>630-920-1900</phone>
    </contact>
    <investigator>
      <last_name>Vassilios Dimitropoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arlington Dermatology</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>847-392-5440</phone>
    </contact>
    <investigator>
      <last_name>Michael Bukhalo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-516-5030</phone>
    </contact>
    <investigator>
      <last_name>Scott Fretzin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-837-6082</phone>
    </contact>
    <investigator>
      <last_name>Scott Guenthner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>574-204-6432</phone>
    </contact>
    <investigator>
      <last_name>Holly Hake Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialist</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>502-585-9059</phone>
    </contact>
    <investigator>
      <last_name>Cindy Owen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology and Skin Cancer Specialists</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>301-355-3183</phone>
    </contact>
    <investigator>
      <last_name>Benjamin Lockshin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>617-636-7462</phone>
    </contact>
    <investigator>
      <last_name>David Rosmarin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>617-264-5943</phone>
    </contact>
    <investigator>
      <last_name>Joseph Merola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>810-455-1612</phone>
    </contact>
    <investigator>
      <last_name>Fasahat Hamzavi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Dermatology PC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-721-5565</phone>
    </contact>
    <investigator>
      <last_name>Craig Leonardi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, P.C</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>402-697-6599</phone>
    </contact>
    <investigator>
      <last_name>Joel Schlessinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-844-8800</phone>
    </contact>
    <investigator>
      <last_name>George Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DermResearchCenter of New York, Inc</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>631-689-1900</phone>
    </contact>
    <investigator>
      <last_name>Elyse Rafal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>336-716-2768</phone>
    </contact>
    <investigator>
      <last_name>Lindsay Strowd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatologists of Greater Columbus</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>614-947-1716</phone>
    </contact>
    <investigator>
      <last_name>Matthew Zirwas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-844-3178</phone>
    </contact>
    <investigator>
      <last_name>Neil Korman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wright State Univ School of Medicine</name>
      <address>
        <city>Fairborn</city>
        <state>Ohio</state>
        <zip>45324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>937-775-2463</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Travers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-226-3376</phone>
    </contact>
    <investigator>
      <last_name>Phoebe Rich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OHSU Center for Health and Healing</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>503-494-4770</phone>
    </contact>
    <investigator>
      <last_name>Eric Simpson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology and Skin Surgery Center</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>610-594-6660</phone>
    </contact>
    <investigator>
      <last_name>Scott Gottlieb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Laser Center of Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>843-556-8886</phone>
    </contact>
    <investigator>
      <last_name>Todd Schlesinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>843-792-5858</phone>
    </contact>
    <investigator>
      <last_name>Lara Wine Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>832-553-2318</phone>
    </contact>
    <investigator>
      <last_name>Craig Teller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Modern Research Associates PLLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-361-2008</phone>
    </contact>
    <investigator>
      <last_name>Jennifer Cather</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-279-2545</phone>
    </contact>
    <investigator>
      <last_name>Edward Lain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-829-5180</phone>
    </contact>
    <investigator>
      <last_name>John Browning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acclaim Dermatology, PLLC</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>832-770-6388</phone>
    </contact>
    <investigator>
      <last_name>Syed Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah MidValley Dematology</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>801-581-6465</phone>
    </contact>
    <investigator>
      <last_name>Kristina Callis-Duffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jordan Valley Dermatology Center</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>801-316-0266</phone>
    </contact>
    <investigator>
      <last_name>Douglass Forsha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>757-622-6315</phone>
    </contact>
    <investigator>
      <last_name>David Pariser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multicare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>253-572-2842</phone>
    </contact>
    <investigator>
      <last_name>Andrew Pace</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Barrie</city>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Edmonton</city>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Etobicoke</city>
        <zip>M8X 1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Markham</city>
        <zip>L3P1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Montréal</city>
        <zip>H2K4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Peterborough</city>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Surrey</city>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Surrey</city>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Waterloo</city>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Windsor</city>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Samuel Sanchez PSC</name>
      <address>
        <city>Caguas</city>
        <zip>00727</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877463136</phone>
    </contact>
    <investigator>
      <last_name>Samuel Sanchez-Rivera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Alma M. Cruz</name>
      <address>
        <city>Carolina</city>
        <zip>00985</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877691954</phone>
    </contact>
    <investigator>
      <last_name>Alma Cruz Santana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine CAIMED Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7878402505</phone>
    </contact>
    <investigator>
      <last_name>Pedro Vendrell-Benito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group PSC</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877268396</phone>
    </contact>
    <investigator>
      <last_name>Jose Gonzalez-Chavez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/eczema/JAIW#?postal=</url>
    <description>A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis (Eczema) (BREEZE-AD5)</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eczema</keyword>
  <keyword>atopic eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

